Evidence map›Paper›PMID 28469267›Full record

ReviewNature reviews. Rheumatology2017

Epidemiology of sarcopenia and insight into possible therapeutic targets.

Elaine M Dennison, Avan A Sayer, Cyrus Cooper

Registry-linked trialOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nature reviews. Rheumatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07598916 (Sarcopenia Among Patients With Metabolic Dysfunction-associated Steatotic Liver Disease), which is not on this map. Cited by 151 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
151citing papers in PubMed, 12 pooled it
8.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07598916 not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Sarcopenia Among Patients With Metabolic Dysfunction-associated Steatotic Liver Disease

TypeobservationalSponsorAssiut UniversityRan2026 to 2027Enrolled120ConditionsSarcopenia Among Patients With Metabolic Dysfunction-associated Steatotic Liver Disease
3 · Its place in the literature

Who cites it

151 citing papers in PubMed, 12 syntheses or guidelines pooled it, 286 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Trial
  14. Trial
  15. Review
  16. Article
  17. Olfaction and muscle strength in older adults: a longitudinal study.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026
    Article
  18. Review
  19. Review
  20. Article

91 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Elaine M DennisonMRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Tremona Road, Southampton SO16 6YD, UK.
Avan A SayerMRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Tremona Road, Southampton SO16 6YD, UK.
Cyrus CooperMRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Tremona Road, Southampton SO16 6YD, UK.
MRC Lifecourse Epidemiology Unit · GBUniversity of Southampton · GBVictoria University of Wellington · NZ

Funding

Medical Research Council G0400491Medical Research Council MC_U147574212Medical Research Council MC_U147574234Medical Research Council MC_U147574237Medical Research Council MC_U147585819Medical Research Council MC_U147585824Medical Research Council MC_U147585827Medical Research Council MC_UP_A620_1014Medical Research Council MC_UP_A620_1015Medical Research Council MC_UU_12011/1Medical Research Council MC_UU_12011/2Versus Arthritis 19583
6 · The paper itself

Abstract

Musculoskeletal ageing is a major public health concern owing to demographic shifts in the population. Sarcopenia, generally defined as the age-related loss of muscle mass and function, is associated with considerable risk of falls, loss of independence in older adults and hospitalization with poorer health outcomes. This condition is therefore associated with increased morbidity and health care costs. As with bone mass, muscle mass and strength increase during late adolescence and early adulthood, but begin to decline substantially from ∼50 years of age. Sarcopenia is characterized by many features, which include loss of muscle mass, altered muscle composition, infiltration with fat and fibrous tissue and alterations in innervation. A better understanding of these factors might help us to develop strategies that target these effects. To date, however, methodological challenges and controversies regarding how best to define the condition, in addition to uncertainty about what outcome measures to consider, have delayed research into possible therapeutic options. Most pharmacological agents investigated to date are hormonal, although new developments have seen the emergence of agents that target myostatin signalling to increase muscle mass. In this review we consider the current approaching for defining sarcopenia and discuss its epidemiology, pathogenesis, and potential therapeutic opportunities.

Indexed as

AdolescentAdultBody CompositionDietHumansMiddle AgedRisk FactorsSarcopeniaSmokingYoung Adult

Identifiers

PMID28469267
PMCPMC5444517
OpenAlexW2611701272

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.